| Unique ID issued by UMIN | UMIN000042767 |
|---|---|
| Receipt number | R000048815 |
| Scientific Title | Endoscopic ultrasound-guided choledochoduodenostomy without fistula dilation for unresectable malignant distal biliary obstruction: a phase 2 prospective trial |
| Date of disclosure of the study information | 2021/01/14 |
| Last modified on | 2025/12/26 18:31:47 |
Endoscopic ultrasound-guided choledochoduodenostomy without fistula dilation for unresectable malignant distal biliary obstruction: a phase 2 prospective trial
CYCLONE
Endoscopic ultrasound-guided choledochoduodenostomy without fistula dilation for unresectable malignant distal biliary obstruction: a phase 2 prospective trial
CYCLONE
| Japan |
unresectable malignant distal biliary obstruction
| Hepato-biliary-pancreatic medicine |
Malignancy
NO
Efficacy and safety of EUS-CDS without fistula dilation
Safety,Efficacy
Technical success
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
| Maneuver |
EUS-CDS without fistula dilation
| 20 | years-old | <= |
| 100 | years-old | >= |
Male and Female
1) Unresectable malignant distal biliary obstruction.
2) Indication for EUS-CDS procedure.
3) One of the following conditions (1), (2), or (3) is met. (1) Total bilirubin >1.5 mg/dL, (2) AST >100 U/L, or (3) ALT >100 U/L.
4) No parenchymal jaundice.
5) No bleeding tendency (platelets >= 50,000, prothrombin (PT) activity time >= 50%).
6) Hemoglobin level >= 8g/dL.
7) Performance status (ECOG): 0, 1, 2.
8) Age: 20 years or older.
9) Patient's written consent for participation in the study.
1) Judgement unsuitableness by the doctor.
2) Acute cholangitis with moderate or severe in the severity classification.
25
| 1st name | Susumu |
| Middle name | |
| Last name | Hijioka |
National Cancer Center Hospital
Department of Hepatobiliary and Pancreatic Oncology Division
104-0045
5-1-1, Tsukiji, Chuo-Ku, Tokyo, Japan
03-3542-2511
shijioka@ncc.go.jp
| 1st name | Takehiko |
| Middle name | |
| Last name | Koga |
National Cancer Center Hospital
Department of Hepatobiliary and Pancreatic Oncology Division
104-0045
5-1-1, Tsukiji, Chuo-Ku, Tokyo, Japan
03-3542-2511
takehikoga@gmail.com
National Cancer Center Hospital
National Cancer Center Hospital
Japanese Governmental office
National Cancer Center Hospital
5-1-1, Tsukiji, Chuo-Ku, Tokyo, Japan
03-3542-2511
NCC_IRBoffice@ml.res.ncc.go.jp
NO
| 2021 | Year | 01 | Month | 14 | Day |
n/a
Published
https://journals.lww.com/eusjournal/fulltext/2023/09000/prospective_clinical_trial_of_eus_guided.3.a
24
Technical Success 100%
| 2025 | Year | 12 | Month | 26 | Day |
Retrospective Study
Retrospective Study
Nil
Technical Success
Completed
| 2021 | Year | 01 | Month | 28 | Day |
| 2021 | Year | 01 | Month | 22 | Day |
| 2021 | Year | 02 | Month | 01 | Day |
| 2022 | Year | 07 | Month | 14 | Day |
| 2022 | Year | 07 | Month | 14 | Day |
| 2022 | Year | 07 | Month | 14 | Day |
| 2023 | Year | 03 | Month | 31 | Day |
| 2020 | Year | 12 | Month | 16 | Day |
| 2025 | Year | 12 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048815